ABSTRACT
OBJECTIVE: To evaluate clinical features and complications in patients with bowel endometriosis submitted to hormonal therapy. METHODS: Retrospective study based on data extracted from medical records of 238 women with recto-sigmoid endometriosis treated between May 2010 and May 2016. RESULTS: Over the course of follow-up, 143 (60.1%) women remained in medical treatment while 95 (39.9%) presented with worsening of pain symptoms or intestinal lesion growth (failure of medical treatment group), with surgical resection performed in 54 cases. Women in the Medical Treatment Group were older (40.5±5.1 years versus 37.3±5.8 years; p<0.0001) and had smaller recto sigmoid lesions (2.1±1.9 versus 3.1±2.2; p=0.008) compared to those who had failed to respond to medical treatment. Similar significant reduction in pain scores for dysmenorrhea, chronic pelvic pain, cyclic dyschezia and dysuria was observed in both groups; however greater reduction in pain scores for dyspareunia was noted in the Surgical Group. Subjective improvement in pain symptoms was also similar between groups (100% versus 98.2%; p=0.18). Major complications rates were higher in the Surgical Group (9.2% versus 0.6%; p=0.001). CONCLUSION: Patients with recto-sigmoid endometriosis who failed to respond to medical treatment were younger and had larger intestinal lesions. Hormonal therapy was equally efficient in improving pain symptoms other than dyspareunia compared to surgery, and was associated with lower complication rates in women with recto-sigmoid endometriosis. Medical treatment should be offered as a first-line therapy for patients with bowel endometriosis. Surgical treatment should be reserved for patients with pain symptoms unresponsive to hormonal therapy, lesion growth or suspected intestinal subocclusion.
Subject(s)
Contraceptives, Oral, Combined/therapeutic use , Endometriosis/drug therapy , Pelvic Pain/drug therapy , Progestins/therapeutic use , Rectal Diseases/drug therapy , Sigmoid Diseases/drug therapy , Adult , Chronic Pain , Dysmenorrhea/drug therapy , Dyspareunia/drug therapy , Endometriosis/surgery , Female , Follow-Up Studies , Humans , Medical Records , Pain Measurement , Pelvic Pain/surgery , Recombinant Fusion Proteins , Rectal Diseases/surgery , Retrospective Studies , Sigmoid Diseases/surgery , Treatment OutcomeABSTRACT
PURPOSE: Radiotherapy-induced dysfunction of the gastrointestinal tract is common in cancer patients and has a significant impact on their quality of life. In this study, we investigated the prevalence of breakthrough cancer pain (BTcP) in patients undergoing 3D pelvic radiotherapy and who had proctalgia. METHODS: This observational, multicenter, cross-sectional epidemiological study was performed in 13 Spanish hospitals. Data were obtained on the presence and characteristics of BTcP, demographics, common comorbidities, and treatments prescribed to the patients. RESULTS: The prevalence of BTcP in patients undergoing pelvic 3D external radiotherapy with proctalgia (N = 105) was 48.6% (95% CI 39.0-58.1%). BTcP was further characterized in 59 patients. The mean (± SD) intensity of the BTcP episodes was 7.45 ± 1.47 in a visual analog scale. We found several statistically significant associations between the descriptive variables of BTcP with demographic and clinical variables associated with the tumor or the patient, such as an increased number of BTcP episodes per day depending on the presence or absence of diabetes (p = 0.001, Chi-square) or time to the onset of pain relief depending on the location of the tumor (p = 0.019, Chi-square). Fentanyl was the drug of choice in BTcP episodes for 95% of the patients. CONCLUSIONS: This study demonstrated a high prevalence of BTcP prevalence in cancer patients undergoing pelvic 3D radiotherapy and with proctalgia. Although the variables determining the onset of BTcP are still unclear, our results could help in the design of future clinical studies addressing the treatment of BTcP in these patients.
Subject(s)
Breakthrough Pain/epidemiology , Cancer Pain/epidemiology , Neoplasms/radiotherapy , Pain/epidemiology , Radiotherapy, Conformal/adverse effects , Rectal Diseases/epidemiology , Adult , Aged , Aged, 80 and over , Anus Neoplasms/drug therapy , Anus Neoplasms/radiotherapy , Breakthrough Pain/drug therapy , Breakthrough Pain/etiology , Cancer Pain/drug therapy , Cancer Pain/etiology , Chi-Square Distribution , Cross-Sectional Studies , Endometrial Neoplasms/radiotherapy , Female , Humans , Male , Middle Aged , Neoplasms/drug therapy , Pain/drug therapy , Prevalence , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/radiotherapy , Radiotherapy Dosage , Rectal Diseases/drug therapy , Rectal Neoplasms/drug therapy , Rectal Neoplasms/radiotherapy , Spain/epidemiology , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/radiotherapy , Uterine Cervical Neoplasms/radiotherapyABSTRACT
ABSTRACT Objective: To evaluate clinical features and complications in patients with bowel endometriosis submitted to hormonal therapy. Methods: Retrospective study based on data extracted from medical records of 238 women with recto-sigmoid endometriosis treated between May 2010 and May 2016. Results: Over the course of follow-up, 143 (60.1%) women remained in medical treatment while 95 (39.9%) presented with worsening of pain symptoms or intestinal lesion growth (failure of medical treatment group), with surgical resection performed in 54 cases. Women in the Medical Treatment Group were older (40.5±5.1 years versus 37.3±5.8 years; p<0.0001) and had smaller recto sigmoid lesions (2.1±1.9 versus 3.1±2.2; p=0.008) compared to those who had failed to respond to medical treatment. Similar significant reduction in pain scores for dysmenorrhea, chronic pelvic pain, cyclic dyschezia and dysuria was observed in both groups; however greater reduction in pain scores for dyspareunia was noted in the Surgical Group. Subjective improvement in pain symptoms was also similar between groups (100% versus 98.2%; p=0.18). Major complications rates were higher in the Surgical Group (9.2% versus 0.6%; p=0.001). Conclusion: Patients with recto-sigmoid endometriosis who failed to respond to medical treatment were younger and had larger intestinal lesions. Hormonal therapy was equally efficient in improving pain symptoms other than dyspareunia compared to surgery, and was associated with lower complication rates in women with recto-sigmoid endometriosis. Medical treatment should be offered as a first-line therapy for patients with bowel endometriosis. Surgical treatment should be reserved for patients with pain symptoms unresponsive to hormonal therapy, lesion growth or suspected intestinal subocclusion.
RESUMO Objetivo: Avaliar características clínicas e complicações em pacientes com endometriose intestinal submetidos ao tratamento hormonal. Métodos: Dados de prontuários de 238 pacientes com endometriose de retossigmoide tratadas entre maio de 2010 e maio de 2016 foram coletados para este estudo retrospectivo. Resultados: Durante o período de acompanhamento, 143 (60,1%) mulheres mantiveram tratamento clínico, enquanto 95 (39,9%) tiveram piora dos sintomas de dor ou aumento da lesão intestinal (grupo falha de tratamento clínico), sendo 54 submetidas ao tratamento cirúrgico. As mulheres no Grupo Tratamento Clínico eram mais velhas (40,5±5,1 anos versus 37,3±5,8 anos; p<0,0001) e tinham lesões intestinais menores (2,1±1,9 versus 3,1±2,2; p=0,008) em comparação ao grupo falha de tratamento clínico. Redução significativa e semelhante do escore de dor na dismenorreia, dor pélvica crônica, disquezia cíclica e disúria cíclica foi observada nos Grupos Tratamento Clínico e Cirúrgico. Dispareunia, no entato, teve uma redução maior no Grupo Cirurgia. A redução subjetiva dos sintomas dolorosos também foi semelhante entre os Grupos Clínico e Cirúrgico (100% versus 98,2%; p=0,18). O Grupo Tratamento Cirúrgico foi relacionado a uma maior taxa de complicações graves (9,2% versus 0,6%; p=0,001) em comparação ao Grupo Tratamento Clínico. Conclusão: Falha no tratamento clínico em pacientes com endometriose de retossigmoide foi observada em mulheres mais jovens que tinham lesões intestinais maiores. O tratamento clínico hormonal foi igualmente eficaz na melhora dos sintomas de dor, exceto dispareunia, em comparação ao tratamento cirúrgico em mulheres com endometriose intestinal, mas com menor taxa de complicações. O tratamento clínico deve ser oferecido como primeira opção em pacientes com endometriose intestinal, enquanto o tratamento cirúrgico deve ser reservado para pacientes sem melhora nos sintomas de dor com tratamento hormonal, progressão das lesões ou suspeita de suboclusão intestinal.
Subject(s)
Humans , Female , Adult , Progestins/therapeutic use , Rectal Diseases/drug therapy , Sigmoid Diseases/drug therapy , Pelvic Pain/drug therapy , Contraceptives, Oral, Combined/therapeutic use , Endometriosis/drug therapy , Rectal Diseases/surgery , Sigmoid Diseases/surgery , Pain Measurement , Recombinant Fusion Proteins , Medical Records , Retrospective Studies , Follow-Up Studies , Treatment Outcome , Pelvic Pain/surgery , Dysmenorrhea/drug therapy , Dyspareunia/drug therapy , Endometriosis/surgery , Chronic PainABSTRACT
Introducción: La úlcera solitaria de recto es una entidad patológica crónica, benigna e infrecuente, que en general no se la considera entre los diagnósticos diferenciales de las patologías crónicas del recto. A menudo es subdiagnosticada. Las principales manifestaciones clinicas son: proctorragia, mucorrea, esfuerzo defecatorio y tenesmo. Objetivo: Evaluar las características clinicas de una patología infrecuente del recto, a partir de 3 casos clínicos. Lugar de aplicación: Institución privada. Pacientes y método: Se presentan 3 pacientes con diagnóstico anatomopatológico de úlcera solitaria de recto, entre 2003-2010, dos hombres y una mujer, con un promedio de edad de 53 años (rango 41-70 años). Resultados: La presentación clínica fue proctorragia, mucorrea, tenesmo, proctalgía y esfuerzo defecatorio. En los 3 pacientes la úlcera fue solitaria, dos en pared posterior y una en pared anterior del recto. El diagnostico se realizó por medio de la endoscopía, y biopsia de la lesión. Los 3 casos respondieron favorablemente al tratamiento médico. Conclusiones: La etiología es desconocida. Se la relaciona con trastornos de la defecación. La lesión no siempre es ulcerada ni solitaria. El diagnóstico se realiza por medio de colonoscopía y biopsia, debido a que presenta histología patognomónica. El tratamiento puede ser conservador o quirúrgico.
Introduction: Solitary rectal ulcer is a chronic, benign and infrequent entity, generally not considered in the differential diagnosis of chronic diseases of the rectum. It is often underdiagnosed. The main clinical manifestations include bloody stool, mucorrhea, straining and tenesmus. Objective: To asses the current behavior of a rare disease of the rectum, from 3 clinical cases. Point of application: Private institution. Patients and method: Three patients are presented with pathological diagnosis of solitary rectal ulcer, between 2003 - 2010, two men and a woman, with an average age of 53 years (range 41-70 years). Results: The clinical presentation was bloody stool, mucorrhea. tenesmus, anal pain and straining. In all cases the ulcer was solitary; two in posterior wall and one in anterior wall of the rectum. The diagnosis was made by endoscopy and biopsy of the lesion. The 3 cases responded well to medical treatment. Conclusions: The etiology is unknown. It is related to defecation disorders. The lesion is not always ulcerated of solitary. Diagnosis is made by colonoscopy and biopsy, because it shows pathognomonic histology. Treatment can be conservative or surgical.
Subject(s)
Humans , Male , Adult , Female , Middle Aged , Rectal Diseases/diagnosis , Rectal Diseases/diet therapy , Rectal Diseases/pathology , Rectal Diseases/drug therapy , Rectal Diseases/therapy , Ulcer/diagnosis , Ulcer/drug therapy , Ulcer/therapy , Chronic Disease , Diagnosis, Differential , Endoscopy, Digestive System/methodsSubject(s)
Mycobacterium Infections, Nontuberculous/diagnosis , Rectal Diseases/microbiology , Adult , Comorbidity , HIV Infections/epidemiology , Humans , Male , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium Infections, Nontuberculous/epidemiology , Mycobacterium Infections, Nontuberculous/pathology , Rectal Diseases/drug therapy , Rectal Diseases/epidemiology , Rectal Diseases/pathologyABSTRACT
BACKGROUND AND OBJECTIVES: Radiation proctitis is a common complication after pelvic irradiation. One to five percent of these patients will develop intractable or massive hemorrhagic radiation proctitis that will require repeated hospital admissions and blood transfusions. We evaluated the benefits of instillation of 4% formalin in the management of refractory hemorrhagic radiation-induced proctitis. METHODS: From January 1998 to May 1999, 20 female patients who failed with administration of topical steroids and/or mesalazine were treated with 500 ml of 4% formalin instilled into the rectum in 50-ml aliquots. RESULTS: Median age was 58 years. Eighteen patients had cervical cancer and two, endometrial cancer. These patients received a mean of 7,500 rads to the pelvis. The symptoms began at a mean of 8 months after termination of radiotherapy. Median time of symptomatic rectal hemorrhage was 8 months. Median of blood units previously transfused was six (range: 2-11). Hemorrhage immediately ceased after the 4% formalin instillation in 17 patients. Three patients required formalin instillation repetition with success in one. Overall success was 90%. Median follow-up was 20 months. Five patients had moderate pelvic pain after instillation and one developed rectosigmoideal necrosis that required resection plus Hartmann procedure. Two patients developed rectovaginal fistula and required colostomy, and one thereafter, required abdominoperineal resection en bloc with the posterior wall of the vagina due to pelvis sepsis. CONCLUSIONS: Rectal instillation of 4% formalin is a simple, inexpensive, and efficient treatment for refractory hemorrhagic radiation proctitis.
Subject(s)
Formaldehyde/therapeutic use , Gastrointestinal Hemorrhage/drug therapy , Proctitis/drug therapy , Radiation Injuries/drug therapy , Rectal Diseases/drug therapy , Female , Gastrointestinal Hemorrhage/etiology , Humans , Middle Aged , Proctitis/etiology , Rectal Diseases/genetics , Uterine Cervical Neoplasms/radiotherapySubject(s)
Humans , Rectal Diseases/etiology , Rectal Diseases/prevention & control , Rectal Diseases/drug therapy , Anus Diseases/complications , Anus Diseases/prevention & control , Anus Diseases/drug therapy , Sexually Transmitted Diseases/prevention & control , Sexually Transmitted Diseases/drug therapy , Acquired Immunodeficiency Syndrome/complications , Diagnosis, Differential , Risk Groups , Sexual Behavior , Anus Neoplasms/complications , Anus Neoplasms/mortality , Quality of LifeSubject(s)
Humans , Anus Diseases/complications , Anus Diseases/drug therapy , Anus Diseases/prevention & control , Rectal Diseases/drug therapy , Rectal Diseases/etiology , Rectal Diseases/prevention & control , Sexually Transmitted Diseases/drug therapy , Sexually Transmitted Diseases/prevention & control , Acquired Immunodeficiency Syndrome/complications , Anus Neoplasms/complications , Anus Neoplasms/mortality , Diagnosis, Differential , Quality of Life , Risk Groups , Sexual BehaviorABSTRACT
Cincuenta y nueve pacientes sometidos a cirugía colorrectal electiva recibieron preparación de colon por vía anterógrada y profilaxis antibiótica en dosis única con ceftriaxona y ornidazol. La preparación utilizada fue bien tolerada, obteniendo una adecuada limpieza del lumen intestinal y minimizando las alteraciones hidroelectrolíticas y del equilibrio ácido-base. No hubo sepsis ni complicaciones sépticas graves intraabdominales.